Overview

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Arete Therapeutics
Treatments:
1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-urea
Criteria
Inclusion Criteria:

- mild to moderate hypertension

- naive to antihypertensive medication or on two or less antihypertensive medications

- impaired glucose tolerance

- mild obesity

Exclusion Criteria:

- Diagnosis of Type 1 or Type 2 diabetes

- History of severe heart failure

- AST, ALT levels more than twice the normal range